the 44th yearly Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Demonstrate reveal that Pfizer Inc.’s new investigational microsphere formulation of azithromycin, which is dosed as an onetime-only oral antibiotic, is comparable to other often prescribed treatments for several of the very frequent respiratory tract infections in adult patients.
Zithromax is accessible in america since 1992 under the tradename Azithromycin, you can buy azithromycin here Pfizer sponsored the studies and has submitted the data for review from the U.S. Food and Drug Administration. The Company is seeking acceptance for treating adult respiratory tract infections, including acute bacterial exacerbations of chronic bronchitis (AECB) acute bacterial sinusitis (ABS) and community acquired pneumonia (CAP).
These three studies revealed that with one dose, azithromycin microspheres gives a whole length of therapy for treating AECB, ABS and CAP. Azithromycin microspheres was compared into a seven-day regimen of clarithromycin XL for the treatment of CAP also to seven- and ten-day courses of levofloxacin for treating AECB and ABS, respectively.
“Given the effectiveness of an onetime-dose for all these common diseases and the sure conformity, the hope would be that such regimen will help minimize the development of antibiotic resistance,” said Michael Niederman, M.D., chairman of the Department of Medicine at Winthrop-University Hospital, Mineola, N.Y. and professor of Medicine at the In University of New York at Stony Brook. “Antibiotic resistance is a growing issue in healing community respiratory tract infections, plus among the variables that leads to its growth is patients taking an incomplete class of therapy.”
In two of three multicenter, randomized, double blind, double-dummy trials presented, azithromycin microspheres was compared to levofloxacin. One study analyzed azithromycin microspheres (2.0 grams) and levofloxacin (500 mg/day for seven days) in 446 areas with AECB. The clinical treatment rate in the azithromycin microspheres group was similar (95 percent) to the levofloxacin group (96 percent). Chronic bronchitis is distinguished by excessive cough and sputum production on most days for at least three months during at least two successive years with sporadic acute exacerbations. AECB are typically shown as a gain in dyspnea (difficult or labored respiration), sputum volume and/or sputum purulence (pus).
Azithromycin microspheres was additionally compared to levofloxacin (500 mg/day for ten days) in 541 patients with ABS. Clinical success rates were similar–94.5 percent of patients treated with azithromycin microspheres and 92.8 percent of levofloxacin-treated patients. ABS is an acute disease of the sinuses which can cause nasal congestion, purulent nasal discharge, temperature and facial pain or tenderness.
In a different study presented through the assembly, the newest formula of azithromycin was compared to clarithromycin XL (1 g/day for seven days) in 501 randomized subjects with light-to-moderate CAP. Treatment with azithromycin microspheres resulted in similar pathogen eradication speeds (91.8 percent) vs. clarithromycin XL (90.5 percent). The clinical success rate in the azithromycin microspheres group was 92.6 percent vs. 94.7 percent in the clarithromycin XL group. CAP is a lung disease obtained outside of hospitals or extended-care facilities.